About US
Contact us
-
UPDATED: Judge hits J&J with $1.1B penalty in Risperdal caseJohnson & Johnson ($JNJ) has suffered another Risperdal defeat. And this one is several times larger than the others: An Arkansas judge slapped the drugmaker with $1.1 billion in penalties for dec2012/4/12
-
FDA adds clotting data to Bayer's Yaz, YasminBayer's ($BAYRY.PK)Yaz and Yasmin may be linked to a higher risk of blood clots than other contraceptive pills, the FDA said, but then again, they may not be. To make sure doctors and patients are2012/4/12
-
Patients put a high value on cancer meds--and on hopeThere's been a lot of debate about new and expensive cancer drugs. How much is 6 extra months of life worth? A year? The U.K.'s cost-effectiveness agency tries to answer this question with mathematica2012/4/11
-
Should FDA change its rules to prevent another Tricor?The Archives of Internal Medicine has made a run at the Abbott Laboratories ($ABT) fenofibrate saga. After studying years of prescription data, researchers concluded that branded versions of the drug-2012/4/11
-
AstraZeneca investors lobby for management shake-upThe knives are out at AstraZeneca ($AZN). Investors are agitating for big changes at the troubled drugmaker,even asking for a new CEO, the Financial Times reports. Despairing over the company's recent2012/4/10
-
Novartis CEO explains how and why he cut jobsNovartis ($NVS) CEO Joe Jimenez (photo) tells the company's layoff story to Bloomberg. One nugget: He chose to cut jobs "from a position of strength," rather than wait until poor company performance f2012/4/10
-
U.K. drug costs drop as blockbusters go off patentOn the heels of news that drug spending in the U.S. rose last year, in part because of new branded drugs, the U.K. reports a decline in its pharma costs, thanks to blockbuster medications that lost pa2012/4/9
-
Pfizer shrinks worker severance packagesPfizer ($PFE) CEO Ian Read has vowed to cut $1 billion in operating expenses at the drugmaker this year, and one way he plans to do that appears to be by reducing severance packages, Bloomberg reports2012/4/9
-
'Animal rule' allowed for J&J drug backed for new approvalJohnson & Johnson ($JNJ) has entered some atypical regulatory terrain. FDA advisors have heartily backed approval for the drug giant's antibiotic Levaquin for a new use that the federal government2012/4/6
-
Vaccines group in HPV price talks with Merck, GSKThe global vaccines group GAVI Alliance is nearing a deal to add vaccines against humanpapillomavirus, which can cause cervical cancer, to its offerings. The group says it's negotiating cut-rate price2012/4/6